CORONA Remedies Limited
CORONA Remedies Limited operates in Pharmaceuticals, part of the Healthcare sector. It booked ₹422 cr of revenue in its latest quarter (Q1 FY27) and kept 14.2% of sales as profit.
“is to be among the most appropriate balance of skills and experience.”
Healthier than 62% of companies in Healthcare, on the 5 of 6 measures we could read for it. Each measure is ranked against the 116–150 companies that reported it.
Measures financial condition, not whether to buy. Learn what this score means · How this is calculated
- RSI (14)
- 55
At close. Not part of the score.
How much profit it earns on the money it employs
How much it owes, and whether earnings cover the interest
Whether reported profit actually arrives as cash
What today's price implies, against our models or its peers
How much of the promoters' stake is pledged, and how much they hold · highest in its sector on what we could measure
Not measurable for this company: growth & consistency. Those pillars are left out of the score rather than counted as zero.
What if I invest in CORONA?
Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.
The slider starts at 5%, taken from a generic assumption, not this company's history. That is history, not a forecast — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.
P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-09-17.
An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.
| Revenue from Operations | ₹422 cr |
| Other Income | ₹3 cr |
| Total Income | ₹426 cr |
| Cost of Materials | ₹33 cr |
| Purchases of Stock-in-Trade | ₹57 cr |
| Inventory Change (±) | ₹-12 cr |
| Employee Benefit Expense | ₹122 cr |
| Finance Costs | ₹3 cr |
| Depreciation & Amortisation | ₹13 cr |
| Other Expenses | ₹130 cr |
| Total Expenses | ₹345 cr |
| Profit before Tax | ₹80 cr |
| Tax Expense | ₹20 cr |
| Share of JV / Associates | ₹1 L |
| Net Profit | ₹60 cr |
| Net margin on total income | 14.1% |
| Metric | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|
| Revenue | 342 cr | 353 cr | 422 cr |
| Total income | 345 cr | 357 cr | 426 cr |
| Expenses | 270 cr | 303 cr | 345 cr |
| Profit before tax | 55 cr | 55 cr | 80 cr |
| Tax | 14 cr | 9 cr | 20 cr |
| Net profit (owners' share) | 41 cr | 45 cr | 60 cr |
| Net margin (owners' share, on revenue) | 12.1% | 12.8% | 14.2% |
| EPS (₹) | 6.75 | 7.41 | 9.83 |
| Company | Price | Market cap | P/E | ROE | Net margin | 1-yr return |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹1,867 | ₹4.48 L cr | 38.6 | 13.9% | 18.9% | — |
| Divi's Laboratories Limited | ₹9,323 | ₹2.47 L cr | 68.7 | 21.5% | 29.3% | — |
| Torrent Pharmaceuticals Limited | ₹4,875 | ₹1.65 L cr | 82.0 | 27.0% | 11.5% | — |
| Zydus Lifesciences Limited | ₹1,135 | ₹1.13 L cr | 30.4 | 13.9% | 11.7% | — |
| Cipla Limited | ₹1,376 | ₹1.11 L cr | 35.2 | 9.2% | 11.1% | — |
| Laurus Labs Limited | ₹1,948 | ₹1.05 L cr | 71.5 | 27.7% | 18.1% | — |
| Dr. Reddy's Laboratories Limited | ₹1,175 | ₹98,113 cr | 55.1 | 4.7% | 5.5% | — |
| Aurobindo Pharma Limited | ₹1,690 | ₹97,243 cr | 23.7 | 10.9% | 11.3% | — |
| Lupin Limited | ₹2,098 | ₹95,936 cr | 16.9 | 25.2% | 17.1% | — |
| Action | Detail | Ex-date |
|---|---|---|
| Dividend | ₹10 / share | 19 Jun 2026 |
Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.
The company also transacted with 13 other related parties — subsidiaries, joint ventures, directors and others — that we could not match by name to the promoter list above. Some may still be connected to the family; we only count the ones the filings let us match with certainty.
Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.